May 6, 2024 - The Company plans to initiate the Phase 1 study (OSPREY) of STK-002 for the treatment of Autosomal Dominant Optic Atrophy (ADOA) in 2024.
The treatment of Dravet syndrome a severe and progressive genetic epilepsy seems to be their primary focus.
May 6, 2024 - The Company plans to initiate the Phase 1 study...
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
-0.005(4.55%) |
Mkt cap ! $501.6M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 11.0¢ | 10.5¢ | $115.5K | 1.079M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 31 | 2311396 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 275545 | 7 |
View Market Depth
| Last trade - 11.56am 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
10.5¢ |
Change
-0.005 ( 4.55 %) |
||||
| Open | High | Low | Volume | ||
| 10.8¢ | 10.8¢ | 10.3¢ | 1008561 | ||
| Last updated 12.34pm 30/05/2024 ? | |||||
| PYC (ASX) Chart |